Marin Jose J G, Briz Oscar, Herraez Elisa, Lozano Elisa, Asensio Maitane, Di Giacomo Silvia, Romero Marta R, Osorio-Padilla Luis M, Santos-Llamas Ana I, Serrano Maria A, Armengol Carolina, Efferth Thomas, Macias Rocio I R
Experimental Hepatology and Drug Targeting (HEVEFARM), University of Salamanca, IBSAL, Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain.
Experimental Hepatology and Drug Targeting (HEVEFARM), University of Salamanca, IBSAL, Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain.
Clin Res Hepatol Gastroenterol. 2018 Jun;42(3):182-192. doi: 10.1016/j.clinre.2017.12.006. Epub 2018 Mar 12.
A characteristic shared by most frequent types of primary liver cancer, i.e., hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) in adults, and in a lesser extent hepatoblastoma (HB) mainly in children, is their high refractoriness to chemotherapy. This is the result of synergic interactions among complex and diverse mechanisms of chemoresistance (MOC) in which more than 100 genes are involved. Pharmacological treatment, although it can be initially effective, frequently stimulates the expression of MOC genes, which results in the relapse of the tumor, usually with a more aggressive and less chemosensitive phenotype. Identification of the MOC genetic signature accounting for the "resistome" present at each moment of tumor life would prevent the administration of chemotherapeutic regimens without chance of success but still with noxious side effects for the patient. Moreover, a better description of cancer cells strength is required to develop novel strategies based on pharmacological, cellular or gene therapy to overcome liver cancer chemoresistance.
大多数常见类型的原发性肝癌（即成人肝细胞癌（HCC）和胆管癌（CCA），以及在较小程度上主要发生在儿童中的肝母细胞瘤（HB））的一个共同特征是它们对化疗具有高度耐药性。这是100多个基因参与的复杂多样的化疗耐药机制（MOC）之间协同相互作用的结果。药物治疗虽然最初可能有效，但经常会刺激MOC基因的表达，这会导致肿瘤复发，通常表现为更具侵袭性和化疗敏感性更低的表型。识别在肿瘤生命的每个时刻都存在的构成“耐药组”的MOC基因特征，将避免使用没有成功机会但仍会给患者带来有害副作用的化疗方案。此外，需要更好地描述癌细胞的耐药强度，以开发基于药物、细胞或基因治疗的新策略来克服肝癌的化疗耐药性。
